Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Danaher Corporation (NYSE: DHR) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8‑K, quarterly reports on Form 10‑Q and other disclosures that detail Danaher’s financial performance, governance changes and capital markets activities as a global life sciences and diagnostics innovator.
Danaher uses Form 8‑K filings to report material events such as quarterly and annual financial results, estimated financial performance ahead of investor conferences, amendments to its by‑laws, share repurchase authorizations and changes in senior leadership or board composition. For example, the company has filed 8‑Ks to furnish earnings press releases and presentation slides, to describe updates to its by‑laws regarding shareholder proposal and nomination procedures, and to outline a share repurchase program authorizing the repurchase of up to 35 million shares of common stock.
The filings also list Danaher’s securities registered under Section 12(b) of the Exchange Act, including its common stock and multiple series of senior notes with various maturities, all traded on the New York Stock Exchange. This information helps investors understand the company’s capital structure and the instruments available in public markets.
Through its periodic reports, Danaher provides detailed financial statements, management’s discussion and analysis, and explanations of non‑GAAP measures such as core sales growth and adjusted diluted net earnings per common share. The company explains how it calculates these measures, why management uses them and how they reconcile to the most directly comparable GAAP figures, including adjustments for amortization of acquisition‑related intangible assets, fair value gains and losses on investments, impairments and tax effects.
On Stock Titan, users can review these SEC filings alongside AI‑powered summaries that highlight key points, such as revenue trends, margin drivers, capital allocation decisions, governance changes and risk disclosures. The platform’s tools can help readers quickly understand the implications of Danaher’s 10‑Q and 10‑K reports, as well as 8‑K items related to dividends, share repurchases, executive transitions and by‑law amendments, while still allowing detailed review of the original documents.
Danaher Corporation director and executive committee chairman Mitchell P. Rales reported a bona fide gift of 71,648 shares of Danaher common stock, made through the Mitchell P. Rales Family Trust. After this transfer, that trust held 778,352 shares indirectly. The filing also lists other holdings as of the same date, including 53,228 shares held directly by Rales, 801 shares held indirectly through a 401(k) plan, and 26,171,000 shares held indirectly through single-member LLCs owned by a revocable trust for which he is sole trustee and beneficiary. Additional shares are reported in custodial accounts for his daughter, and Rales expressly disclaims beneficial ownership of those daughter-held shares.
Danaher Corporation executive Julie A. Sawyer Montgomery reported a tax-related share disposition. On
Danaher Corporation files its 2025 annual report detailing a global portfolio focused on biotechnology, life sciences and diagnostics, organized into three main segments. The company emphasizes recurring-revenue lab and clinical products sold largely through direct sales across about 50 countries.
The filing highlights strategic priorities of applying the Danaher Business System, disciplined capital allocation and talent development, supported by more than 60,000 employees. It discusses a pending acquisition of Masimo Corporation, extensive R&D collaborations, and significant international exposure, with about 59% of 2025 sales from customers outside the U.S., including 11% from China.
Danaher outlines broad risk factors: economic and healthcare reimbursement pressures, intense competition and rapid technology change, supply-chain and cybersecurity vulnerabilities, regulatory and environmental obligations, AI-related uncertainties, and challenges tied to global operations and government policies. Human capital, safety, sustainability and regulatory compliance are presented as central to long‑term performance.
Danaher Corporation Executive Vice President Gregory M. Milosevich exercised employee stock options covering 1,320 shares on February 19, 2026, converting them into common stock at an exercise price of $58.5900 per share. On the same day, he sold 1,320 common shares at $208.0110 per share, leaving him with 5,099 directly owned shares. The options had vested in five equal annual installments from their original grant date, as disclosed in the footnote.